Lexeo Therapeutics (LXEO) investor relations material

Deal rationale and strategic fit

• Acquisition expands the FA platform with complementary CNS-targeted gene therapy and diversified modalities, aiming for a comprehensive approach to both cardiac and neurologic manifestations of FA.

• Adds clinical, preclinical, and discovery-stage programs, enhancing multimodal therapeutic capabilities and enabling evaluation of standalone, sequential, or combined use of therapies.

• Strategic collaborations support CNS-targeted gene therapy, innovative delivery strategies, and optimization of gene therapy outcomes for FA-associated neurological disease.

• The strategy is to maximize patient benefit and shareholder value by integrating gene therapy, small molecules, protein replacement, and RNA-based strategies.

• The expanded vision aligns with a focus on high unmet need in cardiovascular and neurological genetic diseases.

Financial terms and conditions

• Mantle Therapeutics will be acquired for $8.3 million upfront in cash and equity, with up to $13 million in milestone payments, totaling $21.3 million.

• Success-based milestone payments are tied to clinical and regulatory achievements.

• Transaction expected to close in Q3 2026, subject to customary closing conditions.

• Cash runway guidance into 2028 remains unchanged and includes plans to advance one acquired program into clinical development.

Synergies and expected cost savings

• The acquired programs and collaborations are complementary to existing assets, leveraging current infrastructure and expertise to maximize efficiency and value.

• Combined portfolio enables evaluation of multiple biologic approaches for FA, both standalone and in combination.

• Disciplined capital allocation and portfolio advancement will focus on programs with the strongest clinical and financial potential.